FDA Events for Abacus Life (ABL)
This section highlights FDA-related milestones and regulatory updates for drugs developed by Abacus Life (ABL).
Over the past two years, Abacus Life has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
PREADISAN™. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
PREADISAN™ - FDA Regulatory Timeline and Events
PREADISAN™ is a drug developed by Abacus Life for the following indication: The PREADISAN™ risk score is a first of its kind tool that integrates biological insights with the assessment of mortality risk over time.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- PREADISAN™
- Announced Date:
- August 19, 2024
- Indication:
- The PREADISAN™ risk score is a first of its kind tool that integrates biological insights with the assessment of mortality risk over time.
Announcement
Abacus Life, Inc announced a new partnership and product launch to revolutionize longevity-based health prediction and actuarial technology.
AI Summary
Abacus Life, Inc. has announced an exciting new partnership with Lorisco Life LLC to revolutionize the field of longevity-based health prediction and actuarial technology. Together, they are launching the innovative PREADISAN™ risk score, which uses cutting-edge machine learning and modern proteomics to analyze blood-based biomarkers alongside traditional risk factors.
This breakthrough tool offers highly personalized insights, enabling more accurate forecasting of longevity and mortality risks. By integrating advanced AI models with detailed biological data, the PREADISAN™ risk score provides a tailored approach that can help design better financial products and improved retirement planning solutions for Abacus clients. This partnership is set to transform health prediction by offering customized, data-driven strategies that enhance both health and actuarial planning for a more secure financial future.
Read Announcement
Abacus Life FDA Events - Frequently Asked Questions
As of now, Abacus Life (ABL) has not received any FDA approvals for its therapy in the last two years.
In the past two years, Abacus Life (ABL) has reported FDA regulatory activity for PREADISAN™.
The most recent FDA-related event for Abacus Life occurred on August 19, 2024, involving PREADISAN™. The update was categorized as "Provided Update," with the company reporting: "Abacus Life, Inc announced a new partnership and product launch to revolutionize longevity-based health prediction and actuarial technology."
Currently, Abacus Life has one therapy (PREADISAN™) targeting the following condition: The PREADISAN™ risk score is a first of its kind tool that integrates biological insights with the assessment of mortality risk over time..
More FDA Event Resources from MarketBeat
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
This page (NASDAQ:ABL) was last updated on 7/11/2025 by MarketBeat.com Staff
